Results 71 to 80 of about 5,279 (205)

Budget impact of Paxlovid

, 2022
Analysis of the Budgetary impact of paxlovid for the treatment of adults who do not require supplemental oxygen and who are at increased risk for progression to severe coronavirus disease 2019 (COVID-19) in Brazil Health SystemTHIS DATASET IS ARCHIVED AT
Instituto Nacional de Cardiologia, N (via Mendeley Data)
core   +1 more source

Investigating the Binding Mode of a Naphthol‐Based Inhibitor Targeting SARS‐CoV‐2 Main Protease

ChemMedChem, Volume 21, Issue 16, 27 August 2026.
A highly integrated workflow combining various computational, biophysical, and biochemical methods guides the discovery and characterization of an original naphthol‐based scaffold with inhibitory activity against the main protease of SARS‐CoV‐2 and demonstrates the efficiency of a sophisticated, open‐access consensus ranking protocol for virtual ...
Ifigeneia Akrani, Haifa El Kilani, Franck Touret, Sophia Kouvali, Veronika Gourni, Aggeliki Tsoka, Joulia K. Tsetis, Constantinos Vorgias, Rolf Hilgenfeld, Ioannis K. Kostakis, Vassilios Myrianthopoulos, Emmanuel Mikros   +11 more
wiley   +1 more source

Fact sheet for Paxlovid. Arabic

, 2021
Title from PDF caption (viewed on January 3, 2022)."OHA4029E12292021 ARABIC"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

Data_Sheet_1_Cost-effectiveness of Paxlovid in reducing severe COVID-19 and mortality in China.docx

, 2023
ObjectivesTo assess the cost-effectiveness of Paxlovid in reducing severe COVID-19 and its associated morality, and to investigate the affordable price of Paxlovid in China.Materials and methodsUsing a Markov model, two interventions by Paxlovid ...
Lanfang Li (324704), Qiao Liu, Dan Liu, Weina Zhang (128757), Qiao Liu (346535), Zhen Zhou (184390), Guan Wang (109695), Dan Liu (108669), Guan Wang, Weina Zhang, Lanfang Li, Zhen Zhou   +11 more
core   +1 more source

Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore

BMC Public Health
Introduction Antiviral treatment can reduce the burden of COVID-19. But utilisation can be suboptimal, even in a setting like Singapore where it is fully subsidized for those with selected medical conditions and older adults (≥ 50 years).
Sheng En Alexius Matthias Soh, Wei Ling Brenda Ong, Tun-Linn Thein, Konstadina Griva, I.-Cheng Mark Chen   +4 more
doaj   +1 more source

Exploration of Nirmatrelvir Derivatives as Optimized SARS‐CoV‐2 Antivirals

ChemMedChem, Volume 21, Issue 15, 14 August 2026.
Structure‐guided optimization of nirmatrelvir identifies aldehyde and dichloroacetamide warheads and a potency‐enhancing S4 thioamide. Crystal structures reveal an S2 rearrangement extending toward Cys44, suggesting a new covalent‐design opportunity.
Yugendar R. Alugubelli, Veerabhadra R. Vulupala, Kai S. Yang, Kaustav Khatua, Lauren R. Blankenship, Sathish Kumar, Demonta Coleman, Xuejiao Guo, Zhi Zachery Geng, Chia‐Chuan D. Cho, Banumathi Sankaran, Benjamin W. Neuman, Shiqing Xu, Wenshe Ray Liu   +13 more
wiley   +1 more source

Demographic and clinical details of patients that received Paxlovid.

, 2023
Demographic and clinical details of patients that received Paxlovid.
Jonathan S. Thompson (14797132), Amanda T. Goodwin (3141891), Ian P. Hall (7377620)   +2 more
core   +1 more source

Survival benefit and safety evaluation of probiotic supplementation in omicron‐infected patients: Real‐world evidence from a multicenter 12,615‐patient cohort

VIEW, Volume 7, Issue 4, August 2026.
Probiotic supplements have shown benefits in reducing all‐cause mortality among hospitalized patients with SARS‐CoV‐2 infection. Patients with severe illness or without antiviral treatment were more likely to use probiotic supplements. Probiotic supplements may be a promising adjunctive therapy for SARS‐CoV‐2 infection.
Mengzhao Yang, Shanshuo Liu, Junyi Sun, Fuwei Wang, Guangyun Zhu, Xinjun Hu, Guowu Qian, Yiqiang Yuan, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Zujiang Yu, Zhigang Ren   +14 more
wiley   +1 more source

Comparative evaluation of authorized drugs for treating Covid‐19 patients

Health Science Reports, 2022
Background and Aims Vaccines are the first line of defense against coronavirus disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid‐19 pandemic.
Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, Md. Rabiul Islam   +3 more
doaj   +1 more source

Fact sheet for Paxlovid. Portuguese

, 2021
Title from PDF caption (viewed on January 3, 2022)."OHA4029E12292021 PORTUGUESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core